Kantarjian Hagop M, Thomas Deborah, Ravandi Farhad, Faderl Stefan, Jabbour Elias, Garcia-Manero Guillermo, Pierce Sherry, Shan Jianquin, Cortes Jorge, O'Brien Susan
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2010 Dec 15;116(24):5568-74. doi: 10.1002/cncr.25354. Epub 2010 Aug 24.
Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide-ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics.
Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration <1 year were analyzed. Multivariate analyses for subsequent CR and survival were conducted.
Seventy-five of 245 patients (31%) achieved CR. The median CR duration was 5 months, the median survival was 4.7 months. In multivariate analysis, independent poor prognostic factors for not achieving CR were age >55 years, bone marrow blasts ≥20%, and platelet count <75 × 10(9) /L. Variables that were associated independently with shorter survival were age >55 years, bone marrow blasts ≥20%, platelet count <75 × 10(9) /L, albumin level <3 g/L, and lactic dehydrogenase level ≥1000 IU/L. Patients who had ≥3 of the 5 adverse factors (45%) had a median survival of 2 to 3 months and CR rates of 8% to 15%. Achieving CR was associated independently with improved survival in a landmark multivariate analysis (P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03-0.72).
The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival.
成年急性淋巴细胞白血病(ALL)患者挽救治疗的结果差异很大,取决于多种疾病和患者特征。本研究的目的是通过对患者和疾病特征进行多变量分析,确定成年ALL患者首次挽救治疗后的预后情况。
分析对一线治疗原发耐药或首次完全缓解(CR)持续时间<1年疾病复发的成年ALL患者。对后续CR和生存情况进行多变量分析。
245例患者中有75例(31%)实现CR。CR持续时间的中位数为5个月,生存中位数为4.7个月。在多变量分析中,未实现CR的独立不良预后因素为年龄>55岁、骨髓原始细胞≥20%以及血小板计数<75×10⁹/L。与较短生存期独立相关的变量为年龄>55岁、骨髓原始细胞≥20%、血小板计数<75×10⁹/L、白蛋白水平<3 g/L以及乳酸脱氢酶水平≥1000 IU/L。有5项不良因素中≥3项的患者(45%)生存中位数为2至3个月,CR率为8%至15%。在一项标志性多变量分析中,实现CR与生存期改善独立相关(P<.0001;风险比,0.40;95%置信区间,0.03 - 0.72)。
当前分析确定了首次挽救治疗中一部分成年ALL患者,对其采用标准治疗的结果极差。结果还证实了实现CR对提高生存率的重要性。